Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC).
作者
Alexander Starodub,D. Ross Camidge,Ronald J Scheff,Sajeve Samuel Thomas,Michael J. Guarino,Gregory A. Masters,Kevin M. Kalinsky,Leena Gandhi,Aditya Bardia,Wells A. Messersmith,Allyson J. Ocean,Pius P. Maliakal,Robert M. Sharkey,Francois E. Wilhelm,David M. Goldenberg,Rebecca Suk Heist
8559 Background: Sacituzumab govitecan (IMMU-132) is a novel ADC comprising SN-38, the active metabolite of the topoisomerase inhibitor, irinotecan, conjugated to an anti-Trop-2 humanized antibody. Its uniquely very high drug:antibody ratio of 7.6 allows delivering up to 136-fold more SN-38 than its parent drug, irinotecan, in a human cancer xenograft. The mAb and ADC are immunotherapeutic in vitro (ADCC). Expression of Trop-2 is increased in most epithelial cancers (>80%), including SCLC. Therefore, the efficacy and safety of this new ADC is being examined in previously treated mSCLC. Methods: A Phase I/II clinical trial (ClinicalTrials.gov, NCT01631552) is enrolling mSCLC pts, administering IMMU-132 on days 1 and 8 of 21-day treatment cycles. Treatment continues based on tolerance or until progression, with safety and response assessments (RECIST 1.1) made every week and at 8-12 weeks, respectively. No prophylactic diarrhea or G-CSF medication is given. Results: Thirty-one mSCLC pts were enrolled by 11/19/15. Twenty-eight pts are assessable [median age 63 yrs, 10 M/18 F, ECOG 0 (N=5)/1 (N=23)], with a median of 2.5 (range: 1-5) prior chemotherapies. Pts were given IMMU-132 doses at 8 mg/kg (N=15) or 10 mg/kg (N=13). All pts had previous treatment with platinum-based therapy and etoposide, and 9 had received topotecan. Responses are shown in the Table. Among reported adverse events so far (n=27), grade 3+ drug-related toxicities above 5% incidence are neutropenia (33%) and diarrhea (7%). No pt developed antibodies (by ELISA) to the antibody or drug. Conclusions: Encouraging objective responses with a good therapeutic index support further study of IMMU-132 in pts with previously treated mSCLC. Clinical trial information: NCT01631552.IMMU-132 Dosage Objective Response Rate (PR) including confirmed and unconfirmed data Clinical benefit (PR+ SD > 4 Months Median Progression-Free Survival (Months) (% Maturity) Median Overall Survival (Months) (% Maturity) 8 mg/kg (N=15) 15% 31% 2.0 (87%) 8.1 (60%) 10 mg/kg (N=13) 31% 54% 4.6 (77%) 8.3 (46%)